Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
641-660 of 1,307 trials

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Zimberelimab and Domvanalimab Study

We are comparing a new treatment combination with chemotherapy to standard treatment for patients with untreated metastatic non-small cell lung cancer. This study aims to see which option may help improve survival and response rates.

Metastatic Non–Small Cell Lung CancerConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colon Cancer: Personalized Treatment Strategy

We are exploring whether a blood-based genomic approach can improve outcomes for patients with operable Stage III and high-risk Stage II colon cancer compared to standard chemotherapy. This study also looks at side effects and quality of life.

Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesNeurology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesGastroenterologyInternal Medicine

Antiplatelet Therapy Reduction in High Bleeding Risk Patients

We are studying whether lowering the dose of antiplatelet medication helps patients with acute coronary syndrome who have had stents placed, while reducing the risk of bleeding. The trial compares different medication regimens to find the best balance between safety and effectiveness.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Lower Limb Trauma: Rivaroxaban vs. Heparin

We are studying whether Rivaroxaban is as effective as low-molecular weight heparin in preventing blood clots in patients with lower limb injuries. This trial is for those at high risk of complications while in a cast or brace.

Lower Limb Trauma Requiring Immobilization≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyOrthopedics and Traumatology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

We are studying whether pegozafermin can improve liver health in people with MASH and fibrosis compared to a placebo. This trial will help us understand its safety and effectiveness over time.

Nonalcoholic Fatty Liver Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Melanoma Treatment: Short vs. Long Immunotherapy

We are studying whether 6 months of immunotherapy after surgery is as effective as 12 months for patients with high-risk malignant melanoma. This could help determine the best treatment duration for better outcomes.

Skin Cancer (Melanoma)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyOncology

Chronic Low Back Pain: Stem Cell Injection Study

We are investigating whether injecting stem cells into the spine can help reduce pain and improve function in people with chronic low back pain from degenerative disc disease. This trial is for those who haven't responded to traditional treatments.

Degenerative Disc Disease>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Ketamine for Reducing Opioid Use in Severe Trauma

We are studying whether low doses of ketamine can help reduce the need for morphine in patients with severe trauma. This trial will also look at pain control and any side effects during treatment.

Traumatism>2 yearsConfirmation phase (III)Investigational MedicinesInternal MedicineOtolaryngologyPsychiatry

Meniscal Pain Relief: Betamethasone Infiltration Study

We are testing whether ultrasound-guided betamethasone injections can reduce pain in adults with degenerative meniscal injuries. This study compares the treatment to a placebo to assess its effectiveness and safety.

Meniscal Pain3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Cardiac Arrest: Amiodarone Treatment Study

We are investigating whether giving amiodarone to critically ill patients after a cardiac arrest can lower the risk of death and serious heart rhythm problems. This study focuses on patients with a shockable rhythm and aims to improve their outcomes.

Out-of-Hospital Cardiac Arrest>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology